536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Start SIP in NOVELIX

Start SIP

Performance

  • Low
  • ₹54
  • High
  • ₹54
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹70
  • Open Price₹54
  • Previous Close₹57
  • Volume17,860

Investment Returns

  • Over 1 Month + 1.77%
  • Over 3 Month + 31.75%
  • Over 6 Month + 93.06%
  • Over 1 Year + 134.52%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 89.7
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 87
  • P/B Ratio
  • Average True Range
  • 3.24
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 2.75
  • RSI
  • 46.01
  • MFI
  • 30.24

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹53.94
-2.83 (-4.99%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹57.66
  • 50 Day
  • ₹52.78
  • 100 Day
  • ₹46.62
  • 200 Day
  • ₹37.68

Resistance and Support

53.94 Pivot Speed
  • R3 53.94
  • R2 53.94
  • R1 53.94
  • S1 53.94
  • S2 53.94
  • S3 53.94

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 84.87 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 64% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 7% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 99 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results
2025-04-12 Others Inter-alia, to consider 1. Convening of an EGM for appointment of Non-Executive Independent Director of the Company. 2. To appoint a scrutinizer for the upcoming EGM. 3. Other business matters.

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

54.82%
39.06%
6.12%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹53 As on 09 December, 2025 | 08:38

The Market Cap of Novelix Pharmaceuticals is ₹87.1 Cr As on 09 December, 2025 | 08:38

The P/E ratio of Novelix Pharmaceuticals is 89.7 As on 09 December, 2025 | 08:38

The PB ratio of Novelix Pharmaceuticals is 3.7 As on 09 December, 2025 | 08:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23